- Home
- OABI vs ANNX Comparison
OABI vs ANNX Comparison
Compare OABI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- ANNX
- Stock Information
- Founded
- OABI 2012
- ANNX 2011
- Country
- OABI United States
- ANNX United States
- Employees
- OABI 114
- ANNX N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- ANNX Health Care
- Exchange
- OABI Nasdaq
- ANNX Nasdaq
- Market Cap
- OABI 228.9M
- ANNX 253.8M
- IPO Year
- OABI N/A
- ANNX 2020
- Fundamental
- Price
- OABI $1.57
- ANNX $2.12
- Analyst Decision
- OABI Strong Buy
- ANNX Strong Buy
- Analyst Count
- OABI 3
- ANNX 5
- Target Price
- OABI $6.67
- ANNX $13.00
- AVG Volume (30 Days)
- OABI 385.0K
- ANNX 1.4M
- Earning Date
- OABI 08-06-2025
- ANNX 08-14-2025
- Dividend Yield
- OABI N/A
- ANNX N/A
- EPS Growth
- OABI N/A
- ANNX N/A
- EPS
- OABI N/A
- ANNX N/A
- Revenue
- OABI $23,027,000.00
- ANNX N/A
- Revenue This Year
- OABI N/A
- ANNX N/A
- Revenue Next Year
- OABI $44.99
- ANNX N/A
- P/E Ratio
- OABI N/A
- ANNX N/A
- Revenue Growth
- OABI 6.05
- ANNX N/A
- 52 Week Low
- OABI $1.22
- ANNX $1.29
- 52 Week High
- OABI $4.87
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- OABI 38.28
- ANNX 43.29
- Support Level
- OABI $1.51
- ANNX $2.03
- Resistance Level
- OABI $1.73
- ANNX $2.28
- Average True Range (ATR)
- OABI 0.12
- ANNX 0.12
- MACD
- OABI -0.01
- ANNX 0.01
- Stochastic Oscillator
- OABI 11.32
- ANNX 27.69
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.